RxDoctor Payments Data

Leonard Harris, MD

Hematology & Oncology · Germantown, TNNPI 1518014307

Payments from drug & device makers

$9,467in general payments, 2019–2025

Across 192 payments — averaging $49.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Pfizer$769
  • Seagen Inc.$449
  • Bristol Myers Squibb$424
  • Takeda Pharmaceuticals U.S.A., Inc.$359
  • plus $3K from 39 others

What the payments were for

  • Consulting fees$3,94442%
  • Food & beverage$4,91052%
  • Education$6136%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,467 in reported general payments places this provider in the 40th percentile of 251 hematology & oncology providers in Tennessee.

See all hematology & oncology providers in Tennessee

Medicare billing

Part B allowed, 2024
$2,276,465
Medicare patients
573
Services billed
92,512

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide40$536,740
RevlimidLenalidomide23$382,689
JakafiRuxolitinib Phosphate17$288,964
Darzalex FasproDaratumumab-Hyaluronidase-Fihj15$148,428
VenclextaVenetoclax21$146,637
TruximaRituximab-Abbs15$71,161
EliquisApixaban55$49,271
Cefdinir29$1,189
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen20$1,130
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen41$1,100
Dexamethasone42$910
Hydroxyurea21$787
Famciclovir11$687
Acyclovir34$564
Prochlorperazine Maleate35$482

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$424$382,68923 claims
Incyte CorporationJakafi$48$288,96417 claims
AbbVieVenclexta$59$146,63721 claims
PfizerEliquis$769$49,27155 claims
Lilly USA, LLCOlanzapine$264$35424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 251 hematology & oncology providers in Tennessee.

Other hematology & oncology in Germantown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →